Skip to content

VIROLOGYCONSULT.COM

Virology, antivirals and vaccines

Search for:

Home
Coronovirus (Covid-19)
Respiratory Virus
- Coronavirus
  - COVID-19
- RSV
- Influenza
- Rhinovirus
- HMPV
Other Viruses
- Ebola
- HIV
- Mumps
- Rubulavirus
- Ebola
- Measles
- Biography
The Team
About Virology Consult Ltd.
Resources
- WorkPlacewellness.life
Contact Us

13th September 2020 by Rob LW

Bookmark

Six days after a startling trial halt, AstraZeneca gets a green light to resume dosing their Oxford Covid-19 vaccine –

Six days after an abrupt and startling halt of their late-stage study of the Oxford vaccine for Covid-19, AstraZeneca is back in business. And we also learned on Saturday that Pfizer and BioNTech are boosting the size of their fast-running Phase III, with plans to add 14,000 people to the

Sourced through Scoop.it from: endpts.com

Share this:

Click to share on LinkedIn (Opens in new window)
Click to share on Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
Click to share on WhatsApp (Opens in new window)
Click to email this to a friend (Opens in new window)
Click to print (Opens in new window)

Related

Scoop.it

Post navigation

← Coronavirus testing system ‘falling over’

Six days after a startling trial halt, AstraZeneca gets a green light to resume dosing their Oxford Covid-19 vaccine – →

Category Cloud

Adjuvant africa America america antibody ANTIGEN Antiviral Asthma Australia Bacterial Bad News B cells Book Business reports CDC Childhood chloroquine Climate Clinical Trial coinfection Coronavirus Country COVID-19 Dignostic Disease Drug Resistance Ebola economic epidemiology Epidemiology Excecise Good New HIV HMPV Human Challenge Studies IgA IgG Immunology Immunotherapy India Influenza Japan LMIC masks Measles Mental Health Misc Monoclonal Antibodies Mortality Mumps Official Guidance Other Publications Other Viruses Pandemic Pathogenecity PCR Pneumonia Politics Publications Respiratory Respiratory Virus Rhinovirus RSV Rubulavirus SARS Schistosoma mansoni Social T cells Testing Treatment Upcoming Conferences Vaccines WHO Work Place Wellness

Theme: Business Identity by We Cobble.

We have daily and weekly curated newsletters.

Just click above to choose your options.

This website uses cookies to improve your experience.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Send to Email Address Your Name Your Email Address

Cancel

Post was not sent - check your email addresses!

Email check failed, please try again

Sorry, your blog cannot share posts by email.